Bio-Nanotechnology and Biomedical Nanotechnology

DISCLAIMER! This category has not been updated in a very long time; due to limited resources we have to focus on other categories. The materials listed here are old (and only a small proportion of the available literature on this topic), but they are still useful.

- Research Articles [0]
- Reports and Websites [0]

Abstract [1]

Chan, V.S.W. (December 2006). Nanomedicine: An unresolved regulatory issue. Regulatory Toxicology and Pharmacology, 46 (3): 218-224.

Dailey, L.A., Jekel, N., Fink, L., Gessler, T., Schmehl, T., Wittmar, M., Kissel, T., and Seeger, W. (August 2006). Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicology and Applied Pharmacology Volume 215, Issue 1: 100-108. Abstract [2]. Article [3]

Editorial. (August 2007). Healthy challenges. Nature Nanotechnology, 2, 45. Editorial [4]

Faunce, T.A. (Winter 2007). Nanotechnology in global medicine and human biosecurity: Private interests, policy dilemmas, and the calibration of public health law. The Journal of law, medicine & ethics35(4): 629. Article [5]

Fletcher, B. L., Hullander, E. D., Melechko, A. V., McKnight, T. E., Klein, K. L., Hensley, D. K., Morrell, J. L., Simpson, M. L., Doktycz, M. J. (2004). Microarrays of biomimetic cells formed by the controlled synthesis of carbon nanofiber membranes. Nano Letters, 4(10): 1809-1814.

Flesken-Nikitin, A., Toshkov, I., Naskar, J. (October 2007). Toxicity and Biomedical Imaging of Layered Nanohybrids in the Mouse. Toxicologic Pathology, 35(6): 804 - 810. Abstract [6]

Garnett, M. C., and Kallinteri, P. (August 2006). Nanomedicines and nanotoxicology: some physiological principles. Occupational Medicine, 56: 307 - 311. Abstract [7]. Article [8].

Hardman, R. (2005). A toxicological review of quantum dots: Toxicity depends on physico-chemical and environmental factors. Environmental Health Perspectives, 114(2): 165-172. Accessed on March 5, 2006. Article - PDF [9]

Hunter, A. C. & Moghimi, S. M. (2002). Therapeutic synthetic polymers: a game of Russian roulette? Drug Discovery Today, 7, 998-1001.

Ito, Y; Venkatesan, N; Hirako, N; Sugioka, N; Takada, K. (June 2007). Effect of fiber length of carbon nanotubes on the absorption of erythropoietin from rat small intestine. International Journal Of Pharmaceutics, 337 (1-2): 357-360. Abstract [10].

Jin, Y., Kannan, S., Wu,M. and Zhao, J.X. (2007). Toxicity of Luminescent Silica Nanoparticles to Living Cells. Chem. Res. Toxicol., Abstract [11]

Khetan, S.S, Collins, T.J (2007). Human Pharmaceuticals in the Aquatic Environment: A Challenge to Green Chemistry. Chem. Rev., 107(6): 2319 -2364. Article [12]

Krajl, M., & Pavelic, K. (2003). Medicine on a small scale. European Molecular Biology Organization, 4(11): 1008-1012.

Kreuter, J. Shamenkov, D., Petrov, V., Ramge, P. Cychutek, K., Koch-Brandt, C., Alyautdin, R. (2002). Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of Drug Targeting, 10(4), 317-325.

Kuo, JHS; Jan, MS; Lin, YL. (July 2007). Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers. Journal of Controlled Release, 120(1-2): 51-59. Abstract [13].

Lead, J.R., Wilkinson, K,J. (2006). Aquatic colloids and nanoparticles: Current knowledge and future trends. Environmental chemistry, 3(3): 159-171. Abstract [14].

Lacerda, L., Bianco, A., Prato, M., Kostarelos, K. (2006). Carbon nanotubes as nanomedicines: From toxicology to pharmacology. Advanced Drug Delivery Review.

Li, J., Wu, C., Dai, Y., Zhang, R., Wang, X., Fu, D., and Chen, B. (February 2007). Doxorubicin-CdS Nanoparticles: A Potential Anticancer Agent for Enhancing the Drug Uptake of Cancer Cells. Journal of Nanoscience and Nanotechnology, 7;3:435–439

Maysinger, D. (2007). Nanoparticles and cells: good companions and doomed partnerships. Organic & Biomolecular Chemistry, 5(15): 2335-2342. Article [15]

Medina, C., Santos-Martinez, M.J., Radomski, A., Corrigan, O.I, and Radomski, MW. (March 2007). Nanoparticles: pharmacological and toxicological significance. British Journal of Pharmacology, 150(5): 552–558. Article [16]

Mehra, NK; Jain, AK; Lodhi, N. et al. (2008). Challenges in the Use of Carbon Nanotubes for Biomedical Applications. Critical reviews in therapeutic drug carrier systems, 25(2): 169-206. Abstract [17].

Memisoglu-Bilensoy, E., Dogan, A.L. & Atilla Hincal, A. (2006). Cytotoxic evaluation of injectable cyclodextrin nanoparticles. Journal of Pharmacy and Pharmacology. 58: 585-589.

Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan G., Wu, A. M., Gambhir, S. S. & Weiss, S. (2005). Quantum dots for live cells, in vivo imagine, and diagnostics. Science, 307: 538-544.

Moghimi, S. J., Hunter, A. C, & Murray, J. C. (2005). Nanomedicine: current status and future prospects. The FASEB Journal, 19Â¸311-330.

Monti, D., Moretti, L., Salvioli, S., Straface, E., Malorni,
W., Pellicciari, R., Shettini, G., Bisaglie, M., Pincelli, C., Fumelli, C., Bonafe, M., & Franceshi, C. (2000). C60 carboxyyfullerene exerts a protective activity against oxidative stress-induced apoptosis in human peripheral blood mononuclear cells. Biochemical and Biophysical Research Communications, 3(2): 711-717.

Morey, T. E., Varshney, M., Flint, J. A., Seubert, C. N., Smith, W. B., & Bjoraker, D. G. et al. (2004). Activity of microemulsion-based nanoparticles at the human bio-nano interface: Concentration-dependent effects on thrombosis and hemolysis in whole blood. Journal of Nanoparticle Research, 6, 159-170.

Patra, H.K., Banerjee, S., Chaudhuri, U. (June 2007). Cell selective response to gold nanoparticles. Nanomedicine, 3 (2): 111-119.

Popov, A.M., Lozovik, Y.E. (2007). Biocompatibility and applications of carbon nanotubes in medical nano robots. International Journal of Nanomedicine, 2(3): 361-372. Abstract [18].

Reijnders, L. (June 2007). Biological effects of nanoparticles used as glidants in powders Powder Technology, 175 (3): 142-145.

Reilly, R.M. (July 2007). Carbon nanotubes: Potential benefits and risks of nanotechnology in nuclear medicine. Journal of Nuclear Medicine, 48(7): 1039-1042. Article [19].

Rihova, B. (1996). Biocompatibility of biomaterials: Hemocompatibility, immunocompatibility, and biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. Advanced Drug Delivery Reviews, 21, 157-176.

Rosi, N.I., Giljohann, D.A., Thaxton, C.S., Lytton-Jean, A.D., Han, M.S., & Mirkin, C.A. (2006). Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science, 312-(5776): 1026-1030.

Singh, R., Pantarotto, D., Lacerda, L., Pastorin, G., Klumpp, C., Prato, M., Bianco, A., and Kostarelos, K. (February 2006). Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. PNAS, Volume 103, no. 9, 3357-3362. Abstract [20]. Article [21]

Tucker, J.B. & Zilinskas, R.A. (2006, Spring). The promise and perils of synthetic biology. The New Atlantis-A Journal of Technology and Society. Article [22]

Tyshenko, M.G. (2008). Medical nanotechnology using genetic material and the need for precaution in design and risk assessments. International Journal of Nanotechnology, 5(1): 116 - 123. Abstract [23]

Vashist, S.K., Tewari, R., Bajpai, R.P., Bharadwaj, L.M., and Raiteri, R. (September 2006). Review of Quantum Dot Technologies for Cancer Detection and Treatment. Azojono. Article [24]

Yamakoshi, Y., Umezawa, N., Ryu, A., Arakane,K., Miyata, N., Goda, Y., Masumizu, T. and Nagano, T. (September 2003). Active Oxygen Species Generated from Photoexcited Fullerene (C60) as Potential Medicines: O2- versus O2. JACS, 125, 12803-12809.

Zhang, Y.D., Hu, Z.Y., Ye, M.Y. et al. (May 2007). Effect of poly(ethylene glycol)-block-polylactide nanoparticles on hepatic cells of mouse: Low cytotoxicity, but efflux of the nanoparticles by ATP-binding cassette transporters. European Journal of Pharmaceutics and Biopharmaceutics, 66 (2): 268-280.

Website with link to PDF [25]

European technology platform on Nanomedicine. (November 2006). Nanomedicine: Nanotechnology for Health. Report [26]

European Technology Platform on Nanomedicine. (September 2005). Nanotechnology for Health. Report [27]

Nanomedicine website: Link [28].

National Cancer Institute, NCI Alliance for Nanotechnology in Cancer (also includes links to news on nanotechnology in health & medicine): Website [29]

Last updated July 2008 - Mathilde Colin